| Biotechnology Industry | Healthcare Sector | - CEO | TWSE Exchange | TW0006872005 ISIN |
| Taiwan Country | - Employees | - Last Dividend | 23 Jan 2024 Last Split | - IPO Date |
NaviFUS Corp. is a pioneering medical device company based in Taipei, Taiwan, focusing on the development and commercialization of focused ultrasound (FUS) solutions tailored for unmet needs within the realm of neuromedicine. Since its inception in 2015, NaviFUS Corp. has dedicated itself to advancing medical technology, specifically through the innovative application of FUS systems, to address various neurological conditions. The company's commitment to enhancing patient care and outcomes is evident in its pursuit of creating cutting-edge solutions that facilitate targeted treatments and interventions in the brain with high precision and minimal invasiveness.
The flagship product of NaviFUS Corp., NaviFUS, is a state-of-the-art neuronavigator-guided transcranial Focused Ultrasound (FUS) system. It is ingeniously designed to deliver focal energy with precision into deep brain tissues. This innovative approach allows for non-invasive treatments targeting specific brain areas, with potential applications spanning from targeted drug delivery and neuromodulation to immuno-stimulation. Its versatility and precision make it a groundbreaking tool in the treatment and management of neurological conditions.
NAVIRFA represents another significant technological advancement from NaviFUS Corp., incorporating a sophisticated optical 3D surgical tracking mechanism. This navigation system is crucial for ultrasonic interventional procedures, particularly in monitoring the 3D position of the needle tip throughout the process. It enhances the accuracy, safety, and effectiveness of FUS-based interventions, thereby optimizing patient outcomes in various therapeutic contexts.